ArTS Archivio della ricerca di Trieste

ROVIELLO, GIANDOMENICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.289
EU - Europa 3.824
AS - Asia 3.361
SA - Sud America 427
AF - Africa 72
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 5
Totale 15.994
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.182
PL - Polonia 1.722
SG - Singapore 1.259
CN - Cina 766
IT - Italia 532
HK - Hong Kong 353
SE - Svezia 345
BR - Brasile 333
VN - Vietnam 329
DE - Germania 200
FR - Francia 155
FI - Finlandia 152
RU - Federazione Russa 131
UA - Ucraina 129
KR - Corea 123
GB - Regno Unito 116
TR - Turchia 116
IN - India 92
BD - Bangladesh 82
IE - Irlanda 78
BG - Bulgaria 72
CA - Canada 67
NL - Olanda 56
AR - Argentina 35
JP - Giappone 32
ES - Italia 31
IQ - Iraq 31
MX - Messico 26
MA - Marocco 24
MY - Malesia 22
ID - Indonesia 21
BE - Belgio 18
PK - Pakistan 18
EC - Ecuador 17
IL - Israele 15
SA - Arabia Saudita 15
AT - Austria 14
CH - Svizzera 12
CO - Colombia 11
JO - Giordania 11
AE - Emirati Arabi Uniti 10
AU - Australia 10
GR - Grecia 10
TN - Tunisia 10
CL - Cile 9
TW - Taiwan 9
IR - Iran 8
KE - Kenya 8
NP - Nepal 8
PH - Filippine 8
RO - Romania 8
DZ - Algeria 7
EG - Egitto 7
UZ - Uzbekistan 7
ZA - Sudafrica 7
NZ - Nuova Zelanda 6
PE - Perù 6
PT - Portogallo 6
VE - Venezuela 6
CZ - Repubblica Ceca 5
JM - Giamaica 5
MD - Moldavia 5
PY - Paraguay 5
TH - Thailandia 5
LT - Lituania 4
NO - Norvegia 4
OM - Oman 4
SI - Slovenia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AO - Angola 3
AZ - Azerbaigian 3
BO - Bolivia 3
DK - Danimarca 3
HN - Honduras 3
LB - Libano 3
AL - Albania 2
EE - Estonia 2
ET - Etiopia 2
GA - Gabon 2
GE - Georgia 2
HU - Ungheria 2
KG - Kirghizistan 2
RS - Serbia 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BS - Bahamas 1
GT - Guatemala 1
GY - Guiana 1
HR - Croazia 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LV - Lettonia 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SN - Senegal 1
Totale 15.990
Salva come PNG Salva come JPEG
Città #
Warsaw 1.646
Fairfield 1.006
Ashburn 929
Singapore 824
Woodbridge 605
Houston 524
Wilmington 446
Seattle 428
Chandler 424
Ann Arbor 401
Cambridge 385
Hong Kong 340
San Jose 331
Beijing 217
Santa Clara 189
Jacksonville 187
Trieste 164
Princeton 143
Boardman 123
Seoul 110
Chicago 104
Columbus 97
Ho Chi Minh City 97
Izmir 96
Dallas 86
Council Bluffs 85
Helsinki 83
Los Angeles 80
Dublin 78
Hefei 76
Lauterbourg 74
Sofia 71
Moscow 63
Zgierz 59
New York 56
San Diego 56
Hanoi 54
Munich 51
The Dalles 49
Milan 47
Frankfurt am Main 43
Buffalo 38
Dearborn 37
Dong Ket 34
Bremen 32
London 26
São Paulo 26
Redwood City 25
Tokyo 23
Orem 22
Turku 21
Atlanta 20
Tianjin 20
Mumbai 19
Nuremberg 19
Phoenix 19
Shanghai 19
Casablanca 17
Toronto 17
Brussels 16
Dongguan 16
Guangzhou 16
San Francisco 16
Chennai 15
Miano 15
Lappeenranta 14
Da Nang 13
Duino-Aurisina 13
Falls Church 13
Hangzhou 13
Nanjing 13
Amsterdam 12
Denver 12
Hamilton 12
Rome 12
Des Moines 11
Kunming 11
Montegaldella 11
Norwalk 11
Poplar 11
Amman 10
Boston 10
Düsseldorf 10
Jinan 10
Lahore 10
Montreal 10
Redondo Beach 10
Rio de Janeiro 10
Tel Aviv 10
Fremont 9
Shenzhen 9
Udine 9
Changsha 8
Decatur 8
Guayaquil 8
Haiphong 8
Madrid 8
Portsmouth 8
Riyadh 8
Shenyang 8
Totale 11.818
Salva come PNG Salva come JPEG
Nome #
Advances in systemic therapy for metastatic breast cancer: future perspectives 422
PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene 401
Isolated testicular metastasis from prostate cancer 377
Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer 371
Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma 370
Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma 369
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 353
Bevacizumab in small cell lung cancer 351
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer 349
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 339
Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials 325
Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma 306
Corticosteroid switch after progression on abiraterone acetate plus prednisone 306
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma 286
Apatinib for the treatment of gastric cancer 282
Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer 282
Advances in systemic therapy for malignant mesothelioma: Future perspectives 276
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy 268
Lenvatinib for the treatment of renal cell carcinoma 267
The prognostic value of PI3K mutational status in breast cancer: A meta-analysis 243
Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis 236
Immune checkpoint inhibitors in pre-treated gastric cancer patients: Results from a literature-based meta-analysis 236
The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials 231
Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer? 230
Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter? 228
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer 221
Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives (Medical Oncology, (2017), 34, 7, (119), 10.1007/s12032-017-0975-5) 220
Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? 217
Tumour Infiltrating Lymphocytes and Immune-Related Genes as Predictors of Outcome in Pancreatic Adenocarcinoma 216
Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies before and after Chemotherapy 215
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination with Eribulin in Triple-Negative Breast Cancers 209
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer 203
Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer? 202
Different efficacy of ramucirumab in patients with metastatic gastric and gastroesophageal junction cancer according to ECOG performance status 198
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer 197
A Phase II study of olaparib in breast cancer patients: Biological evaluation from a 'window of opportunity' trial 192
Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials 187
Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer 182
Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer 182
Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: A literature-based meta-analysis of randomized trials 177
Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer? 174
Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel 168
EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience 166
Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience 165
Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis 160
Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis 160
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer 159
Familial aggregation of gastric cancer with microsatellite instability** 158
Is there a place for bevacizumab in patients with extensive-stage small cell lung cancer? 157
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials 156
Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis 156
Avelumab in gastric cancer 154
Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials 150
Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis 150
No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials 149
Apatinib in metastatic gastric cancer: Can paclitaxel make the difference? 148
Single Center Experience on Anatomy-and Histopathology-Based Gastric Cancer Molecular Classification 146
Surgical management of advanced gastric cancer: An evolving issue 138
Neoadjuvant chemotherapy and radical radiotherapy associated with cetuximab for laryngeal cancer in a pancreas and renal recipient 137
New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials 137
Expanding treatment options for metastatic gastric cancer 136
Is the Gleason score the driver for the treatment decision-making of patients with castration-resistant prostate cancer in the new era of the anti-androgenic therapies? 136
Is it time for everolimus-based combination in castration-resistant prostate cancer? 136
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature 134
Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis 132
Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033 128
Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies 128
Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis 127
Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives 127
Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer 124
Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment 122
Cancer management during the COVID-19 world pandemic 121
Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer 115
Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035: Corticosteroid-associated Adverse Events in Elderly Patients 115
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials 106
Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: An evolving issue 103
Immune-gene signature: A new tool for patient selection for checkpoint inhibitors? 86
Current Trends in Liquid Biopsy Tracking Resistance in Molecular Breast Cancer-Targeted Therapies 82
P53 antibodies as a diagnostic marker for cancer: A meta-analysis 77
The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study 71
Effects of Whole Pelvic Radiotherapy on the Distribution of Lymphocyte Subpopulations in Prostate Cancer Patients 68
New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When 60
DNA repair deficiency as circulating biomarker in prostate cancer 48
Totale 16.292
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.963
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.963
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022858 78 76 58 40 8 70 53 33 130 118 61 133
2022/20231.260 109 145 131 185 113 213 14 104 160 14 46 26
2023/2024773 36 83 45 56 34 74 141 153 2 42 50 57
2024/20252.227 27 200 377 134 171 294 101 85 261 215 189 173
2025/20264.114 415 195 181 341 405 345 601 148 405 666 218 194
2026/202791 91 0 0 0 0 0 0 0 0 0 0 0
Totale 16.292